4D Path

About 4D Path

4D Path Inc., established in 2017, operates at the intersection of oncology, pathology, and artificial intelligence. The company was founded by a team with deep expertise in their respective fields: Satabhisa Mukhopadhyay, PhD, who serves as the Chief Executive & Science Officer; Tathagata (Das) Dasgupta, the President, Chief Technology & Compliance Officer; and Partha Mitra, PhD, who holds the position of Chief of Research & Development and Chair of the Scientific Advisory Board. Their combined backgrounds in physics, mathematics, computational science, and life sciences form the foundation of the company's approach to cancer diagnostics.

The core of 4D Path's business is a patented precision oncology platform that analyzes digitized hematoxylin and eosin (H&E) stained tissue images, the most common type of biopsy slide, to extract critical biomarker information. This process aims to provide a comprehensive patient profile from a single image, potentially eliminating the need for a series of slower and more expensive molecular tests like immunohistochemistry (IHC) or next-generation sequencing (NGS). The business model centers on offering this technology as a Software as a Medical Device (SaaMD), providing clinical solutions for both companion diagnostics and translational medicine to pathology labs, hospitals, and pharmaceutical companies conducting clinical trials. The goal is to reduce costs and shorten the time from biopsy to actionable clinical insight.

A significant milestone was achieved when the U.S. Food & Drug Administration (FDA) granted Breakthrough Device Designation to its first product, the 4D Q-plasia OncoReader for Breast cancer. This software functions as an adjunct tool for histopathologists, designed to enhance the accuracy of diagnosing key features of breast cancer, such as its grade and invasiveness, directly from standard biopsy images. This designation suggests the technology has the potential to offer a substantial improvement over the current standard of care, democratizing access to advanced diagnostics by leveraging existing pathology workflows.